Inovytec Named Smart 50 Awards Recipient for Development of Smart Critical Aid Solution, SALI

Inovytec, a developer of medical devices that address emergency and routine respiratory and cardiac care, announced today that it has been recognized by the 2021 Smart 50 Awards for the implementation of SALI, a clinically proven, smart critical aid system that enables bystanders to provide treatment to people experiencing a medical emergency.

The Smart 50 Awards, in partnership with Smart Cities Connect, Smart Cities Connect Foundation, and US Ignite, annually recognize the most innovative and influential global smart city projects.

SALI, housed in a small case, is placed in public areas around a city. When someone experiences a cardiac or medical emergency, a bystander can easily deploy the SALI and place the patient on a headrest inside. The device is equipped with tools for non-invasive airway management, automated oxygen therapy, vital monitoring, and defibrillation. A video screen inside guides the bystander through providing basic first aid and attaching the monitoring tools. SALI also automatically connects to an emergency dispatch center, enabling interactive instruction from a medical professional and real-time transmission of vital signs for improved treatment and outcomes.

A study of the SALI’s implementation in Marburg, Germany found that the SALI reduced the time to first medical treatment by six minutes and 12 seconds. This time is critical for improving patient outcomes and reducing neurological damage. SALI was also chosen to be part of a national project in Romania, led by the Deputy Minister responsible for Emergency Healthcare and Services. Initial deployment is 240 devices in supermarkets and 140 in the municipal areas of Bucharest.

“The smart city revolution centers on utilizing new technology for the betterment of millions of people,” said Inovytec CEO Udi Kantor. “SALI helps cities create connected safe zones within which people are significantly more protected in emergency situations. It empowers community members to be responsible for one another and take action before the arrival of the emergency response team. We are honored to win this award and I’m proud of our team for helping to push patient safety forward.”

SourceInovytec

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version